Biomarkers For Ad

Alzheimer's disease and dementia are neurodegenerative conditions that gradually impair cognitive function and memory. Alzheimer's, the most common form of dementia, typically manifests through progressive memory loss, confusion, and difficulty in reasoning or problem-solving. As these diseases advance, individuals may experience changes in behavior, language difficulties, and even challenges with motor functions.

Recent research focuses on identifying biomarkers—indicators in blood, cerebrospinal fluid, or brain imaging—that could aid in early diagnosis and monitoring of Alzheimer's. These biomarkers include beta-amyloid and tau proteins, which accumulate abnormally in the brains of affected individuals. Advances in biomarker detection offer promise for earlier intervention and more precise tracking of disease progression, potentially leading to improved management strategies and therapeutic developments in the future. Understanding these biomarkers is crucial for developing effective treatments and enhancing the quality of life for those living with Alzheimer's and dementia.

Committee Members
Speaker at Alzheimer’s Disease, Dementia & Cognitive Disorders Conference 2027 - Jun Hua

Jun Hua

Johns Hopkins University , United States
Speaker at Alzheimer’s Disease, Dementia & Cognitive Disorders Conference 2027 - Nazneen N Dewji

Nazneen N Dewji

Cenna Biosciences Inc, United States
Speaker at Alzheimer’s Disease, Dementia & Cognitive Disorders Conference 2027 - Jacqueline London

Jacqueline London

Paris Diderot University, France

Submit your abstract Today

Whatsapp